Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.44 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.44 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 6/20 | 0.42 |
| ▸ | NOS1 | P29475 | 2/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 5/20 | 0.38 |
| ▸ | NPC1 | O15118 | 3/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | ATM | Q13315 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
| ▸ | TP53 | P04637 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15549396 | 0.95 | LMNA (0.46) | LMNAHSD17B10GABRA5GABRB2SMN1; SMN2 | |
| SCHEMBL20000852 | 0.92 | GABRA5 (0.47) | LMNAHSD17B10GABRA5GABRB2SMN1; SMN2 | |
| SCHEMBL17709923 | 0.79 | HTR6 (0.34) | NPC1 | |
| SCHEMBL17710056 | 0.75 | NPC1 (0.33) | RAB9ANPC1KDM4E | |
| SCHEMBL17709818 | 0.75 | CNR1 (0.37) | RAB9ANPC1KDM4ETP53 | |
| SCHEMBL17709961 | 0.75 | HTR6 (0.35) | LMNAHSD17B10GABRA5GABRB2SMN1; SMN2 | |
| SCHEMBL28161480 | 0.74 | CNR1 (0.38) | SMN1; SMN2RAB9AALDH1A1TP53 | |
| SCHEMBL2820205 | 0.74 | CNR1 (0.40) | LMNASMN1; SMN2RAB9ANPC1ALDH1A1 | |
| SCHEMBL28160951 | 0.74 | HTR6 (0.39) | SMN1; SMN2RAB9AALDH1A1 | |
| SCHEMBL17709913 | 0.74 | CNR1 (0.34) | NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-107108598-B | Thiazoles as Ror gamma t modulators | 詹森药业有限公司 | 2020-11-17 | — | — | CN | disclosed |
| EP-3212641-B1 | THIAZOLES AS MODULATORS OF RORYT | JANSSEN PHARMACEUTICA NV (BE) | 2018-12-05 | — | — | EP | disclosed |
| US-10080744-B2 | Thiazoles as modulators of RORγt | JANSSEN PHARMACEUTICA NV (BE) | 2018-09-25 | — | — | US | disclosed |
| US-20180064690-A1 | THIAZOLES AS MODULATORS OF RORyt | JANSSEN PHARMACEUTICA NV (BE) | 2018-03-08 | — | — | US | disclosed |
| US-20180064690-A1 | THIAZOLES AS MODULATORS OF RORyt | JANSSEN PHARMACEUTICA NV (BE) | 2018-03-08 | — | — | US | disclosed |
| US-20180064690-A1 | THIAZOLES AS MODULATORS OF RORyt | JANSSEN PHARMACEUTICA NV (BE) | 2018-03-08 | — | — | US | disclosed |
| US-9861618-B2 | Thiazoles as modulators of RORγt | JANSSEN PHARMACEUTICA NV (BE) | 2018-01-09 | — | — | US | disclosed |
| US-9861618-B2 | Thiazoles as modulators of RORγt | JANSSEN PHARMACEUTICA NV (BE) | 2018-01-09 | — | — | US | disclosed |
| EP-3212641-A1 | THIAZOLES AS MODULATORS OF RORyt | Janssen Pharmaceutica NV (BE) | 2017-09-06 | — | — | EP | disclosed |
| WO-2016069976-A1 | THIAZOLES AS MODULATORS OF RORyt | JANSSEN PHARMACEUTICA NV (BE) | 2016-05-06 | — | — | WO | disclosed |
| US-20160120850-A1 | THIAZOLES AS MODULATORS OF RORyt | JANSSEN PHARMACEUTICA NV (US) | 2016-05-05 | — | — | US | disclosed |
| US-20160120850-A1 | THIAZOLES AS MODULATORS OF RORyt | JANSSEN PHARMACEUTICA NV (US) | 2016-05-05 | — | — | US | disclosed |
| US-20160120850-A1 | THIAZOLES AS MODULATORS OF RORyt | JANSSEN PHARMACEUTICA NV (US) | 2016-05-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160120850-A1 | THIAZOLES AS MODULATORS OF RORyt | RORC, RORB, RORA | LMNA 4203/4885HSD17B10 1294/4885GABRA5 1738/4885 |
| US-10080744-B2 | Thiazoles as modulators of RORγt | RORB, RORA, RORC | LMNA 4344/4885HSD17B10 1054/4885GABRA5 1008/4885 |
| US-20180064690-A1 | THIAZOLES AS MODULATORS OF RORyt | RORC, RORB, RORA | LMNA 4239/4885HSD17B10 1324/4885GABRA5 1603/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.